Adam ElNaggar

10PUBLICATIONS
119CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNeurology and neuromuscular diseasesMedical biotechnology diagnostics (incl. biosensors)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 26, 2026
ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Ilana B Epstein, Adetolani Odogiyon, Stephanie Berg

|Sep 24, 2025
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Peter W Ketch, Carly Bess Scalise, Fernando Recio

|Sep 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Rebecca Hassoun, Reuben Ben-David, John P Sfakianos

|Aug 01, 2025
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Anne Knisely, Yibo Dai, Graham L Barlow

|Apr 01, 2025
A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations.

Anton Safonov, Tomoki T Nomakuchi, Elizabeth Chao

|Dec 18, 2024
Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.

Arnab Basu, Cherry Au, Ajitha Kommalapati

Pageof 2